Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy Participants
Status:
Recruiting
Trial end date:
2024-04-05
Target enrollment:
Participant gender:
Summary
This study is designed as a randomized, double-blind, parallel-group study to evaluate the
PK, safety, tolerability, immunogenicity, and PD of TUR03 compared to Soliris, when
administered as a single IV infusion in healthy adult male participants.